McKesson Corporation (MCK)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at McKesson Corporation.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 1 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 856.20 $ — 59% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 10.4% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 17
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 03/31/2027 | 44.25 | 44.09 – 44.56 | 431,193 | 13.2% | 17 |
| 03/31/2028 | 50.38 | 49.48 – 52.58 | 463,461 | 13.8% | 17 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 9.44 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 6.94 | 57.10 | 95,294 | 17.80 | 0.90 | -2,383 | -2,579 |
| 2025: Q1 | 10.01 | 66.50 | 90,823 | 18.90 | 1.40 | 7,748 | 7,470 |
| 2025: Q2 | 6.25 | -10.80 | 97,827 | 23.40 | 0.80 | -918 | -1,029 |
| 2025: Q3 | 8.92 | 378.70 | 103,150 | 10.10 | 1.10 | 2,420 | 2,531 |
| 2025: Q4 | 9.59 | 38.10 | 106,158 | 11.40 | 1.10 | 1,232 | 1,124 |
| 2026: Q1 | 13.71 | 37.00 | 96,295 | 6.00 | 1.70 | 3,421 | 3,310 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2017 | 198,533 | 3,357 | 5,183 | 23.24 | 4,744 | 12,600 | 60,969 |
| 2018 | 208,357 | 2,921 | 67 | 0.32 | 4,345 | 11,516 | 60,381 |
| 2019 | 214,319 | 3,078 | 34 | 0.17 | 4,036 | 9,680 | 59,672 |
| 2020 | 231,051 | 3,012 | 900 | 4.95 | 4,374 | 6,711 | 61,247 |
| 2021 | 238,228 | 3,510 | -4,539 | -28.26 | 4,542 | 1,446 | 65,015 |
| 2022 | 263,966 | 2,723 | 1,114 | 7.23 | 4,434 | -1,792 | 63,298 |
| 2023 | 276,711 | 4,453 | 3,560 | 25.04 | 5,159 | -1,490 | 62,320 |
| 2024 | 308,951 | 3,927 | 3,002 | 22.39 | 4,314 | -1,599 | 67,443 |
| 2025 | 359,051 | 4,372 | 3,295 | 25.72 | 6,085 | -1,694 | 75,140 |
| 2026 | 403,430 | 6,454 | 4,762 | 38.37 | 6,155 | -2,172 | 82,323 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
McKesson Corporation bietet Gesundheitsdienste in den USA und international an. Es ist in vier Segmenten tätig: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions und Medical-Surgical Solutions.
| Employees | 41,600 |
|---|---|
| Headquarters | Irving, TX |
| Address | 6555 State Highway 161, 75039 Irving, United States |
| Phone | 972 446 4800 |
| Website | mckesson.com |
| IPO Date | 15. Nov 1994 |
| ISIN | US58155Q1031 |
| Stock Split | 2:1 on 01/05/1998 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Brian S. Tyler Ph.D. | CEO & Chairman | 1967 |
| Michele Lau J.D. | Executive VP & Chief Legal Officer | 1976 |
| LeAnn B. Smith | Executive VP & Chief Human Resources Officer | 1975 |
| Kenny K. Cheung | Executive VP & CFO | 1982 |
| Napoleon B. Rutledge Jr. | Senior VP, Controller & Chief Accounting Officer | 1973 |
| Francisco J. Fraga | Executive VP, Chief Information Officer & CTO | 1973 |
| Jeni Dominguez | Head of Investor Relations | – |
| Kirk Kaminsky | Executive VP & Group President of North American Pharmaceutical Services | – |
| Paul A. Smith | Senior Vice President of Taxes | – |
| Kevin W. Emerson | Senior Vice President of Finance Operations | 1973 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 22. Jul 2026 | Wilson-Thompson Kathleen | Director | Other | 277 | 814.04 | 225,489 |
| 22. Jul 2026 | Caruso Dominic J | Director | Other | 277 | 814.04 | 225,489 |
| 22. Jul 2026 | Martinez Maria | Director | Other | 277 | 814.04 | 225,489 |
| 7. Jul 2026 | Tyler Brian S. | Chief Executive Officer | Sell | 8,463 | 793.56 | 6,715,898 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.